Restoring type VII collagen in skin
- PMID: 35584643
- DOI: 10.1016/j.medj.2022.04.008
Restoring type VII collagen in skin
Abstract
New therapeutic hope is emerging for people with the rare inherited blistering skin disease recessive dystrophic epidermolysis bullosa (RDEB). Gurevich et al.1 have reported early-phase clinical trial data evaluating a topical herpes simplex virus 1 vector to restore missing type VII collagen in RDEB skin and heal wounds.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors have received educational grants from Amryt Pharma (J.A.M.) and Janssen (S.M.L.) and have undertaken paid consulting work for Replay (J.A.M.), Almirall (J.A.M.), La Roche Posay (J.A.M.), and Pierre Fabre (J.A.M.).
Comment on
-
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.Nat Med. 2022 Apr;28(4):780-788. doi: 10.1038/s41591-022-01737-y. Epub 2022 Mar 28. Nat Med. 2022. PMID: 35347281 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources